Search research articles
Contact Us
Filters
Showing results (161-170 of 165) with videos related to
Page
of 17
Sort By:
You have reached the last page of results.
This site can display upto 165 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
May 31, 2026
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)
Emma C Tallantyre, Sarah M Planchon, Harriet Howard, et al.
Lancet (London, England)
|
October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial
Jeremy Chataway, Thomas Williams, James Blackstone, et al.
BMJ Open
|
September 16, 2024
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK
James Blackstone, Thomas Williams, Jennifer M Nicholas, et al.
Health Technology Assessment (Winchester, England)
|
June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial
Thomas Williams, James Blackstone, Nevin John, et al.
Nature Genetics
|
October 1, 2013
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
, Ashley H Beecham, Nikolaos A Patsopoulos, et al.
Page
of 17
Search research articles
Search
Showing results (161-170 of 165) with videos related to
Sort By:
Page
of 17
You have reached the last page of results.
This site can display upto 165 results.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
May 31, 2026
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)
Emma C Tallantyre, Sarah M Planchon, Harriet Howard, et al.
Lancet (London, England)
|
October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trial
Jeremy Chataway, Thomas Williams, James Blackstone, et al.
BMJ Open
|
September 16, 2024
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UK
James Blackstone, Thomas Williams, Jennifer M Nicholas, et al.
Health Technology Assessment (Winchester, England)
|
June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial
Thomas Williams, James Blackstone, Nevin John, et al.
Nature Genetics
|
October 1, 2013
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis
, Ashley H Beecham, Nikolaos A Patsopoulos, et al.
Page
of 17